Inspire Medical Systems (INSP) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
13 May, 2026Strategic priorities and operational focus
Emphasis on cost discipline and prioritization of spending to navigate top-line challenges while continuing to invest in revenue growth and product development.
Focus on patient outcomes and product effectiveness, with new data supporting long-term cardiovascular health benefits.
Positive persistence and adaptability are highlighted as key values, especially in response to external challenges such as coding changes and reimbursement issues.
Expansion of the market access team and proactive education of centers to ensure proper coding and billing practices.
Strategic reduction in DTC advertising spend and increased investment in field education to support long-term profitability.
Financial guidance and outlook
Guidance was lowered due to a decline in prior authorization submissions, with Q2 expected to be the low point for the year and a 9%-11% top-line decline.
Sequential revenue improvement is anticipated in Q3 and Q4, though year-over-year declines will persist.
Recovery in revenue is expected, but not a return to double-digit growth rates in 2027; growth will build off a lower base as industry experience improves.
Operating margin targets were reduced in line with revenue guidance, but Q1 bottom-line performance exceeded expectations.
Coding, reimbursement, and regulatory environment
Coding changes, particularly the transition from CPT code 64568 to 64582 and the use of modifiers, have created confusion and slowed prior authorizations.
Variability in coding requirements across MACs and states has led to inconsistent billing practices and a need for center-by-center education.
A new CPT code for Inspire V has been submitted and discussed, with potential implementation as early as January 2028 if approved in the current cycle.
The RUC committee will determine the valuation if the code is accepted, with a large pool of experienced surgeons supporting the process.
Latest events from Inspire Medical Systems
- Q1 revenue rose 1.6% to $204.6M, but net loss widened and guidance was cut on reimbursement headwinds.INSP
Q1 20265 May 2026 - All proposals passed amid strong financial growth, leadership updates, and governance reforms.INSP
AGM 20264 May 2026 - 2025 saw double-digit revenue growth, board declassification plans, and expanded ESG initiatives.INSP
Proxy filing20 Mar 2026 - Key votes include director elections, auditor ratification, and board structure changes.INSP
Proxy filing20 Mar 2026 - Inspire V’s launch, reimbursement clarity, and innovation drive growth amid evolving competition.INSP
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - 2025 saw 14% revenue growth, board declassification proposal, and expanded ESG initiatives.INSP
Proxy Filing9 Mar 2026 - Inspire 5 transition boosts outcomes, efficiency, and growth, with strong clinical and market momentum.INSP
UBS Global Healthcare Conference 202513 Feb 2026 - 2026 guidance shows growth but highlights reimbursement and coding risks after strong 2025.INSP
Q4 202512 Feb 2026 - Strong Inspire V launch, clinical results, and digital tools drive rapid growth and expansion.INSP
44th Annual J.P. Morgan Healthcare Conference3 Feb 2026